¿¼²©±¨°à ¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ÿÈÕÇ©µ½
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æרҵ£º [M zc^I&  
NUO,"Bqq  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ =QO1FO  
fQ?n(  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) IU;pkgBj0Y  
PK|`} z9  
1. ICAM-1 PSrt/y!  
h-)A?%Xt  
2. interleukin 12(IL-12) ]!S)O|_D[  
8-l)TTP&.  
3. tumor infiltrating lymphocyte Wcay'#K,  
0e5- \a  
4. TCR/CD3 complex e&]`X HC9  
zI*/u)48  
5. hematopoietin receptor family t+TbCe  
:Y)kKq d  
6. individual idiotype(IdI) 5 /eS1NJ@  
|@n{tog+-  
7. integrin ch2e#Jf8  
J\8l%4q3  
8. colony-stimulatory factor (CSF) VRN9yn2  
>kLH6.  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© uB)6\fkTB  
RU ,N_GV   
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? !`S%l1[Z  
)PZ}^Fa  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ jKi*3-&  
 ,IvnNnl2  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠoG_'<5Bv>  
rp[oH=&  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØϵ¡£ zSM7x  
.g`*cDW^=  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) %a6]gsiv2<  
OL9C #er  
1. ÊÔÊö¸ÉÈÅËصķÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌص㡣Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËؼì²âµÄ·½·¨ºÍÔ­Àí¡£ E@}j}/%'O  
gkn/E}K#  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ä¿Ç°¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) L$kAe1 V^m  
->25$5#  
3. immunoglobulin superfamily (IgSF) KI QBY!N+  
_"Ke=v_5  
4. selectin h sw My  
*A9{H>Vq  
5. anti-idiotypic antibody (¦ÁId) #CP, \G  
_89G2)U=C  
6. major histocompatibility complex(MHC) i/EiUH/~  
?4?jG3p  
7. immunotolerance bQQ/7KM  
\ ozy_s[  
8. biological reponse modifier(BRM) ;= @-j@?  
Id 7  
9. immune reponse gene (Ir gene) j1CD;9i)%  
aJ_Eh(cF  
10. reshaped antibody (or reconstituted antibody) "J:NW_U  
 M!DoR6  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© !VTS $nJ4  
5j 01Mx A  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ DL!s)5!M  
hQx e0Pdt  
2. ϸ°û¶¾ÐÔTÁÜ°Íϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? zO]dQ$r\Z  
K'/x9.'%  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ OHvzK8  
| N,nt@~  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? `8bp6}OD,  
P[oB'  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ m:7bynT{  
oh~Dbu=%  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? XArLL5_L  
\R t  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ nu -w Qr  
y>1 8)8  
¹©Ïû»¯ÄÚ¿ÆרҵÊÔÌ⣺ /qze  
>Cc$ P  
1. Ä¿Ç°ÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? NFPkK?+  
39e oL;O_  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ |(g2fByDf  
'|r !yAO6  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: <(%uOo$  
T^>cT"ux_  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: x7>sy,c  
`8Ix&d3F  
ÃâÒßѧ ^PszZ10T  
]7@Dqd-/S  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 8t; nU;E*  
5=e@yIr'#  
1. CD8 ? ~8V;Qn  
Hu.d^@V  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) 8a1{x(\z.  
S8t9Ms: k  
3. immunoglobulin fold(Ig fold) 0' t)fnI#  
EA72%Y9F  
4. cadherin (Ca-dependent cell adhesion moleculers) :-n4! z"k  
S5M t?v|K  
5. idiotype-anti-idiotypic antibody immune network theory 7="V7  
K[Kc'6G  
6. HLA class II antigen |H49 FL  
,P]{*uqGiB  
7. complementarity-determining region (CDR) Wit1WI;18  
ygG9ht  
8. perforin(or pore-forming protein ,PFP) IAQ=d4V&  
UlR7_   
9. high affinity IL-2 receptor Gl(,%~F9i  
+=v|kd  
10. artificial active immunization B _ >|Mo/  
TDFv\y}yc  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 7}MWmS^8j  
&x}JC/u]fd  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ08Gr  
]T1"3 [si  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 a&JAF?k  
%"tf`,d~3  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ 2]l*{l^ Bl  
riz({  
4. ÊԱȽÏT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃ濹ԭ¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ >ObpOFb%  
x<"e  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐÑ¡Ò»Ìâ,3¡¢4ÌâÖÐÑ¡Ò»Ìâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ä¿Ç°¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ $k dfY'u  
- >2ej4C  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? ;:OJQFu%4  
]pb3 Fm{  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ '5IJ;4 k  
YV9%^ZaN7  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ B{Rig5Sc  
V&G_Bu~  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ =1D*K%  
z&eJ?wb  
ѧ¿Æרҵ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ drH!?0Dpg  
}r N"H4)  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© d 1z   
>?5`FC  
1. immunoglobulin gene rearrangement $>+-=XMVB  
~"(1~7_  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) Y?> S .B7  
f!87JE=<  
3. flow cytometry(FCM) R,(^fM  
<1ai0]  
4. carrier effect Z"P{/~HG  
:x_l"y"  
5. positive selection of T lymphocytes in thymus &#WTXTr0=  
tZ(Wh  
6. mouse TH1(Th1) and TH2(Th2) subsets !-: a`Vs+  
X;-,3dy  
7. perforin (pore-forming protein ,PFP) ]UMwpL&rY  
"~GudK &  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) NKd):>d%  
/wmJMX  
9. SH-2(src-homology region 2) n32?GRp  
H~ (I  
10. Ab2¦Â (internal image) bju 0l[;=  
I@.qon2V  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© &%^[2^H8"  
6~^+</?  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? =uD2j9!"7  
lVMAab  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? LV`- eW  
JG4 Tb{F=  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠXa-]+_?Q  
tEb2>+R  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ 2 !{P<   
qD 2<-E&M/  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ%R(j|a9z  
|i1z47jN6P  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) s*rtm  
x!S8'  
ÃâÒßѧרҵ£º Rnj2Q! C2  
H3MT.Cpd  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ ARslw*SJ  
AX[/S8|6  
2. ÊԱȽÏÈËT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? `lr\V;o!  
I#9A\.pO  
´«È¾²¡Ñ§×¨Òµ£º ]kc]YO7i%R  
z.#gpTXD  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦ÄÜ¿É·¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ 6VRVk7"  
aNfgSo05@n  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØϵ¡£ eD G=-a4  
=T;%R^@  
Ïû»¯×¨Òµ£º ))u$j4 V  
+STT(bMn  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ I C7n;n9  
G| ^tqI  
2.¼òÊöճĤÏà¹ØÁÜ°ÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌص㡣·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? yU&A[DZQ  
CfA F.H  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ w Xfy,W  
m&b!\"0  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 7 -bU9{5  
vP? "MG  
1. Fas(CD95)/FasL BB=%tz`B  
;<MHDm D  
2. common chain of cytokine receptor DS-Kot(k(z  
e$ E=n  
3 . TCR/CD3 complex v-4eN1OS  
liPUK#  
4. negaive selection of thymocytes YgrBIul  
dLG5yx\js  
5. artificial active immune F71.%p7C8"  
ytr~} M%  
6. anti-idiotypic 7teg*M{  
]`]m41+w  
7. IgSF `[/B G)4  
hZ5h(CQ?"#  
8. Integrin +*~?JT  
3x.|g   
9. chemokine \*1pFX#  
jja9:$#  
10. B7/CD28 -i7W|X"  
315Rk!{AJ  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© \} P}H  
r4D6g>)h1q  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ &-s!ko4z  
@tRq(*(/:  
2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣 '72ZLdi}-  
dG TAZ(1W  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 0:Ak 4L6k  
iVREkZ2SC  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£ TBvv(_  
^+Ec}+ Q  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ r8}GiP0|  
[#$z.BoEo  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ tAPqbi$a  
%koHTWT+  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© b-;+&Rb  
Zii<jZ.)<  
1. B7/CD28 -_4U+Cfmtl  
RiIJ#:6+^I  
2. Th1 subset k#w[G L|T  
Kisd.~u8j  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© + i !/J  
qR--lvO  
4. antibody affinity maturation BOoLs(p  
BI3Q~ADV  
5. AP-1 )?:V5U O\  
1ZOHyO  
6. single chain variable fragment£¨ScFv£© W52AX.Nm  
d@8=%x:  
7. NK cell receptor ?A3pXa  
%S]H  
8. Zinkernagel-Doherty phenomenon e@Q<hb0<eU  
0-oR { {  
9. Ig fold .|NF8Fj  
f.!)O@HzH  
10. CD40/CD40L Vp  .($  
~B'K_#  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© .nJErC##  
?H#]+SpOcv  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£ Ec y|l ;  
!=;^Grv>  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ Tar tV3;`  
%K@D{ )r_^  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ -n?}L#4%8  
RXP0 4  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ \Azl6`Em  
% =xR$<D  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ )q&=x 2`  
+R@5e+auQ.  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ 0K <@?cI  
Jtnuo]{R  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ <03@cs  
8l-+ 4~mH  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© o>m Z$  
j(F&*aH78  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© ?vuM'UH-  
WHk/Rg%<  
1.Co-stimulators (or co-stimulating molecules) rlqn39  
2s_shY<=}L  
2.NK-kB PsU.dv[  
QijEb  
3.Immunoglobulin superfamily n*(Vf'k  
RbKAB8  
4.antigen-presenting cell (APC) .%j&#(!  
P/5bNK!  
5.death domain R| [mp%Q  
HUiW#x%;  
6.CCR and CXCR OiH tobM  
p(in.Xz  
7.Lectin (or mitogen) JG @bl  
1A"h!;0  
8.Clusters of differentiation, CD) -fFM-gt^t  
jE|Ju:}&  
9.B7 family -bJht  
"v@$ CR9<T  
10.Cytotoxic T lymphocyte, CTL) pMnkh}Q#  
o<ak&LX`9  
11.IL-15 and IL-15 receptor (IL-15R) 9AK<<Mge.  
":E 7#9  
12.MHC restriction 6C@,&2<yK  
*ci,;-*C  
13.Affinity-chromatography 12BTZ  
A@-nn]  
14.Cyctosprin A, CsA j_Pt8{[  
c'B6E1}sx  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) . #`lW7  
:fz&)e9  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© aTF~rAne<  
sN0S~}F+  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 9,wd,,ta  
W<C \g~\  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ rKEi1b  
Lsv[@Rl  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 ?n<b:oO  
T[*1*303  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© Qz/o-W;  
C%#=@HC  
ÃâÒßѧרҵ£º COPH)Bdq.  
;/?M&rX  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ !wy Qk  
Si#I^aF`%  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ ZYDLl8  
9a}rE  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ )N h67P3X"  
e aLSq  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) |>o]+V  
/W&Ro5-  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) 'L|& qy@  
QCB2&lN\&L  
1. ADCC(antibody dependent cell-mediated cytotoxicity) }= OI (Wy  
2z9\p%MX  
2. »·æß¾úËØ(cyclosporin) W>3[+w B  
I^erMQn[ z  
3. KIR(killer cell inhibitory receptor) LV|ZZ.d h  
F:nhSd  
4. HLDA(human leucocyte differentiation antigen) c\"t+/Z  
+oa\'.~?  
5. Interleukin 18(IL-18) KwGk8$ U  
S+(TRIjk  
6. ÕûºÏËØ(integrin) ":s1}A  
lb M)U  
7. Fas/FasL d%1T v1={  
Ip#BR!$n  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) U9k;)fK  
-*xm<R],  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) { No*Z'X  
~aKM+KmtPH  
10. Th1/Th2 hx|Cam"  
%04N"^mT'~  
11. »ùÒòÒßÃç(DNAÒßÃç) Qtj.@CGB  
05= $Dnv  
12. chemokines and chemokine receptor I5EKS0MQ!  
)1 ]P4  
13. ÃâÒßÄÍÊÜ [:M:6JJ  
M"QT(u+  
14. ¹²´Ì¼¤·Ö×Ó }:JE*D|  
Axb,{X[6g  
15. ËÀÍö½á¹¹Óò(death domain) Py^ _::  
Dn{ hU $*  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) .Up\ 0|b  
Ns?qLSN  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? mOiA}BGw  
TNwBnMe  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ&T7|f!y  
D H7B4P  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î P-B3<~*i!  
gz{~\0y  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ -1\*}m%1e  
S"t6 *fWr  
£¨3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå Gyo[C98  
_<;;CI3w  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ cJb.@8^J  
)8BGN'jyi  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) _8*}S=  
UNx|+  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ ZkbaUIQ  
7d9kr?3(U  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ cvoE4&m!  
m 2tw[6M  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆһϵͳʵÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃÇ°¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»